| Terry Joe Durham, CRNA | |
|
531 7th Ave, Albany, GA 31701-1921 | |
| (229) 438-9922 | |
| (229) 438-9922 |
| Full Name | Terry Joe Durham |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 34 Years |
| Location | 531 7th Ave, Albany, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225156532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN080893 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sweet Dreams Anesthesiology Nurses Of Georgia Llc | 0941456446 | 14 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Sweet Dreams Nurse Anesthesia, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649463365 PECOS PAC ID: 5294823266 Enrollment ID: O20071109000111 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Synergy Anesthesiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003040502 PECOS PAC ID: 4385781954 Enrollment ID: O20091030000317 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Sweet Dreams Anesthesiology Nurses Of Georgia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669737409 PECOS PAC ID: 0941456446 Enrollment ID: O20120816000621 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Sweet Dreams Nurse Anesthesia Of Georgia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003168923 PECOS PAC ID: 7719138353 Enrollment ID: O20121108000271 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Grand Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689230724 PECOS PAC ID: 0345579876 Enrollment ID: O20190910000358 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Radiance Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194381236 PECOS PAC ID: 5890116032 Enrollment ID: O20200526003208 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Entity Name | Vision Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134740319 PECOS PAC ID: 0648691592 Enrollment ID: O20210428000240 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Terry Joe Durham, CRNA 531 7th Ave, Albany, GA 31701-1921 Ph: (229) 438-9922 | Terry Joe Durham, CRNA 531 7th Ave, Albany, GA 31701-1921 Ph: (229) 438-9922 |
News Archive
In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.
A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.
› Verified 3 days ago
Kirby Kitchens, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2311 W Doublegate Dr, Albany, GA 31721 Phone: 229-888-2554 Fax: 229-888-2554 | |
Randall J Cannady, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 417 W 3rd Ave, Albany, GA 31701 Phone: 229-312-5800 Fax: 229-312-5853 | |
Misty Grimes, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 417 W 3rd Ave, Albany, GA 31701 Phone: 229-312-1000 | |
Terrance L Cannon, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 417 W 3rd Ave, Albany, GA 31701 Phone: 229-439-9400 Fax: 229-436-3718 | |
Robert H Nelson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 417 W 3rd Ave, Albany, GA 31701 Phone: 229-312-1000 Fax: 312-312-1215 | |
Mrs. Lisa D Vallely, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2000 Palmyra Rd, Albany, GA 31701 Phone: 229-434-2161 Fax: 229-434-2502 |